Business Context and Reporting Period
Company: Organogenesis Holdings Inc. (ORGO)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2026
Business Overview: A regenerative medicine company focused on advanced wound care and surgical/sports medicine products. The company operates in a single segment and faces significant headwinds from Medicare reimbursement changes and market disruption regarding skin substitute coverage policies.
Key Financial Metrics
| Metric (in thousands) | Q2 2026 | Q2 2025 | 6M 2026 | 6M 2025 |
|---|---|---|---|---|
| Total Revenue | $43,755 | $101,005 | $80,983 | $187,698 |
| Net Product Revenue | $42,805 | $100,779 | $79,055 | $187,472 |
| Net Loss | $(96,267) | $(9,392) | $(149,423) | $(28,235) |
| Net Loss per Share (Basic/Diluted) | $(0.77) | $(0.10) | $(1.21) | $(0.27) |
| Cash and Cash Equivalents | $46,097 | N/A | N/A | N/A |
| Working Capital | $139,700 | N/A | N/A | N/A |
| Debt (Revolving Facility) | $0 | $0 | $0 | $0 |
Note: The company has no outstanding borrowings under its Revolving Facility, which expires on August 6, 2026.
Material Changes vs. Prior Period
- Revenue Decline: Net product revenue decreased 58% year-over-year for the six months ended June 30, 2026. Advanced Wound Care revenue dropped 62% to $65.6 million, driven by clinician confusion and market disruption following CMS comments on discarded products and the withdrawal of Local Coverage Determinations (LCDs).
- Increased Losses: Net loss widened significantly to $149.4 million for the six months ended June 30, 2026, compared to $28.2 million in the prior year period. This was exacerbated by a $30.1 million income tax expense resulting from the establishment of a full valuation allowance against deferred tax assets.
- Restructuring Costs: The company incurred $13.9 million in restructuring charges over the first two quarters of 2026, reducing headcount by approximately 28% (226 employees) and closing the St. Petersburg, Florida facility.
- Asset Held for Sale: A building held for sale was adjusted upward by $1.188 million in Q2 2026 based on a sale agreement finalized in July 2026 for gross proceeds of $3.75 million.
Guidance, Outlook, and Risks
- Regulatory Environment: The company faces uncertainty regarding Medicare reimbursement. CMS finalized rules for 2026 that may materially impact utilization and revenue. The WISeR Model, testing prior authorization in six states, began January 1, 2026, potentially restricting access.
- Product Pipeline:
- ReNu: Rolling Biologics License Application (BLA) submitted April 24, 2026; FDA accepted for review with a PDUFA target date of April 24, 2027.
- Dermagraft: Manufacturing and sales remain suspended. The relaunch is delayed indefinitely due to market decline and revenue pressures; no specific timing can be projected.
- Liquidity: Management expects cash on hand ($46.1 million) and working capital to fund operations for at least 12 months beyond the filing date, despite the credit facility expiration in August 2026.
- Risks: Continued revenue decline, inability to secure additional financing on acceptable terms, and potential failure of the Smithfield, Rhode Island facility build-out to support future manufacturing.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $46.1 million cash balance to cover operations post-August 2026 credit facility expiration.
- Reimbursement Impact: Monitor the actual impact of the 2026 CMS PFS and OPPS final rules on product utilization and pricing.
- Dermagraft Status: Track updates on the Smithfield facility build-out and FDA approval status, as the relaunch of this product is critical for long-term revenue recovery.
- Restructuring Execution: Confirm the realization of cost savings from the 28% headcount reduction and facility closure.
- Deferred Tax Assets: Assess the likelihood of reversing the full valuation allowance on deferred tax assets given the current loss trajectory.